Simponi L929 Neutralisation Assay

The primary mechanism of action of Simponi is the neutralization of circulating TNF-Alpha. TNF-Alpha itself is involved in an array of different signalling pathways and through binding to TNF-Alpha, Simponi has the capacity to neutralize the wide range of different biological activities that are mediated by TNF-Alpha. Historically, anti-TNF-Alpha therapeutic antibody products have used a murine cell line (L929 or WeHi) with a cell death endpoint as the primary potency bioassay.

The principle of the Simponi (golimumab) neutralization bioassay is that the relevant cell line is prepared in cell plates. A dilution series of golimumab is then prepared and added to an optimized concentration of TNF-Alpha and incubated to allow neutralization to occur, prior to addition to the cell plate. The cell plate is then incubated for a further period of time before the assay is completed using the relevant detection methodology. Sample results are routinely reported as a relative potency measurement against the reference standard.

Contact our scientists today to discuss your biosimilar project.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy